Table 2.

Clinical Characteristics of Women with Breast Cancer on Adjuvant Therapy at TASH, Addis Ababa, Ethiopia, June to August 2022 (n = 121)

Variables	Frequency	Percentage	Standardized Mean of Information needs (SD)
Stage
Stage I  Stage II  Stage III  Stage IV	8 39 36 38	6.6 32.2 29.8 31.4	3.72(0.80) 3.78(0.48) 3.73(0.70) 3.81(0.57)
Time Since Diagnosis
<1year  1-2year  2-3years  3-5years  >5years	82 17 9 9 4	67.8 14.0 7.4 7.4 3.4	3.77(0.58) 3.95(0.71) 3.83(0.58) 3.60(0.50) 3.30(0.17)
Type of Surgery
BCS  Mastectomy	10 111	8.3 91.7	3.45(0.65) 3.80(0.58)
Type of Treatment
Single Treatment  Combined Treatment	92 29	76 24	3.82(0.57) 3.60(0.63)
Combination of chemotherapy
AC  AC-T  Other	9 79 33	7.4 65.3 27.3	4.00(0.57) 3.75(0.60) 3.74(0.57)

Note: BCS: Breast Conservative Surgery; AC: Adriamycin and Cyclophosphamide, AC-T: Adriamycin and Cyclophosphamide, and Taxol, Other: Anastrazole, Cyclophosphamide and docetaxel, Single agent docetaxol, Single agent gemcitabine tamoxifen and trastuzumab